1110 completed. 1110 Phase 2, 223 Phase 1, 52 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1110 | Completed 1110 |
| Phase 1 | 223 | Completed 223 |
| Phase 3 | 52 | Completed 52 |
Follow Colonic Diseases: new trials by email Literature Review of Colonic Diseases trials Research Report on Colonic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Rutin on Inflammation Pathways in Ulcerative Colitis Patients Rutin 500 MG Oral Tablet, Fecal Calprotectin, Placebo - Ulcerative Colitis | Phase 2 | Completed | Benha University | 60 | 2025-02-22 | 2026-01-27 |
| COMBO Endoscopy Oropharyngeal Airway in Sedated Gastrointestinal Endoscopy for Obese Patients the COMBO Endoscopy Oropharyngeal Airway - Hypoxia, Esophageal Cancer | Phase 2 | Completed | Zhejiang University | 107 | 2025-02-04 | 2025-05-21 |
| A Study of AC-101 Tablets in Participants With Moderate to Severe Active Ulcerative Colitis AC-101 - Ulcerative Colitis | Phase 1 / Phase 2 | Completed | Accro Bioscience (Suzhou) Limited | 25 | 2025-01-20 | 2026-10-28 |
| Effects of Standardized Boswellia Carterii Extract on Irritable Bowel Syndrome Patients Boswellia carterii Extract, Educationntal program for IBS patie - Irritable Bowel Syndrome | Phase 2 / Phase 3 | Completed | Mansoura University | 60 | 2025-01-01 | 2026-05-08 |
| Fluorescent Approach for Refined Endoscopic Marking With Clip Localization and Identification Procedure Endoscopic Clipping, ICG injection - Colon Cancer | Phase 2 | Completed | Seoul National University Hospital | 110 | 2024-12-10 | 2026-08-05 |
| Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC Cetuximab, Encorafenib - Colorectal Cancer | Phase 2 | Completed | Gruppo Oncologico del Nord-Ovest | 16 | 2024-07-23 | 2026-10-28 |
| Comparison of Rimegepant and Placebo for Pain in IBS Rimegepant 75 MG [Nurtec] - Irritable Bowel Syndrome | Phase 2 | Completed | Mayo Clinic | 39 | 2024-06-06 | 2026-10-15 |
| Trial of Mirtazapine for Depression in IBD Mirtazapine, Placebo - Major Depressive Disorder, Inflammatory Bowel Diseases | Phase 2 | Completed | King's College London | 76 | 2024-05-07 | 2026-08-19 |
| The Effects of Bromelain Supplement in Patients With Ulcerative Colitis Bromlein, Placebo - Ulcerative Colitis, Primary Sclerosing Cholangitis | Phase 2 / Phase 3 | Completed | National Nutrition and Food Technology Institute | 52 | 2024-04-20 | 2026-10-27 |
| A Study to Evaluate the Efficacy and Safety of ZYIL1 Oral Capsules for the Treatment of Patients With Mild to Moderately Active Ulcerative Colitis Resistant or Intolerant to Oral Aminosalicylates Arm1, Arm 2 - Ulcerative Colitis | Phase 2 | Completed | Zydus Lifesciences Limited | 24 | 2024-04-08 | 2024-12-20 |
| Study to Assess Colonic Microbiota Changes in Response to Energy Drink Consumption Energy drink - Colorectal Cancer | Phase 2 | Completed | University of Florida | 76 | 2024-02-28 | 2025-05-06 |
| A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis JNJ-77242113, Placebo - Colitis, Ulcerative | Phase 2 | Completed | Janssen Research & Development, LLC | 252 | 2023-10-09 | 2026-04-13 |
| Immunologic Changes and Recovery-related Factors in Elderly Colon Cancer Patients Blood test - Cancer of Colon, Interleukins | Phase 2 | Completed | Soonchunhyang University Hospital | 75 | 2023-09-04 | 2024-06-12 |
| A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors SNS-101 (anti-VISTA), Cemiplimab - Solid Tumor, Adult, Advanced Solid Tumor | Phase 1 / Phase 2 | Completed | Sensei Biotherapeutics, Inc. | 98 | 2023-05-31 | 2026-09-02 |
| Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers [18F]FAPI-74 PET/CT - Gastrointestinal Cancers, Cholangiocarcinoma | Phase 2 | Completed | SOFIE | 112 | 2023-04-28 | 2026-10-01 |
| An Early Phase 2 Clinical Study of KSP-0243 KSP-0243, Placebo - Colitis, Ulcerative | Phase 2 | Completed | Kissei Pharmaceutical Co., Ltd. | 108 | 2023-04-27 | 2025-03-17 |
| Combination Immunotherapy in Colorectal Cancer Botensilimab, Balstilimab - Colorectal Neoplasms | Phase 2 | Completed | Weill Medical College of Cornell University | 26 | 2023-03-17 | 2026-10-09 |
| Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation Onvansertib, FOLFIRI, Bevacizumab - Colorectal Cancer, Metastatic Colorectal Cancer | Phase 2 | Completed | Cardiff Oncology | 23 | 2023-03-17 | 2025-01-10 |
| Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis ABBV-668 - Ulcerative Colitis | Phase 2 | Completed | AbbVie | 30 | 2023-03-16 | 2025-12-23 |
| A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose Expansion - Cancer, Solid Tumor | Phase 1 / Phase 2 | Completed | Kineta Inc. | 40 | 2023-03-03 | 2026-10-05 |
Showing 20 of 1110. Sign in to see all of them.
Colorectal Neoplasms (735) · Colonic Neoplasms (291) · Rectal Neoplasms (216) · Colitis, Ulcerative (153) · Neoplasm Metastasis (94) · Irritable Bowel Syndrome (91) · Neoplasms (57) · Pancreatic Neoplasms (48) · Breast Neoplasms (47) · Carcinoma, Non-Small-Cell Lung (41) · Inflammatory Bowel Diseases (35) · Ovarian Neoplasms (32) · Stomach Neoplasms (30) · Lung Neoplasms (28) · Gastrointestinal Neoplasms (23)
Intestinal Diseases (1096) · Digestive System Diseases (1095) · Gastrointestinal Diseases (1089) · Neoplasms by Site (851) · Intestinal Neoplasms (849) · Digestive System Neoplasms (848) · Gastrointestinal Neoplasms (834) · Neoplasms (804) · Rectal Diseases (783) · Pathological Conditions, Signs and Symptoms (176) · Gastroenteritis (163) · Colitis (147) · Colorectal Neoplasms (122) · Inflammatory Bowel Diseases (122)
Fluorouracil (148) · Irinotecan (144) · Oxaliplatin (143) · Leucovorin (132) · Bevacizumab (119) · Cetuximab (100) · Capecitabine (90) · Panitumumab (56) · Folfox protocol (36) · IFL protocol (27) · pembrolizumab (24) · Nivolumab (23) · Radiotherapy (19) · regorafenib (19) · Gemcitabine (17)
National Cancer Institute (NCI) (48) · Amgen (21) · Memorial Sloan Kettering Cancer Center (20) · Eli Lilly and Company (19) · Hoffmann-La Roche (18) · Pfizer (17) · Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) (14) · AstraZeneca (12) · Bristol-Myers Squibb (12) · Alliance for Clinical Trials in Oncology (10) · Genentech, Inc. (10) · M.D. Anderson Cancer Center (10) · Federation Francophone de Cancerologie Digestive (9) · Mayo Clinic (9) · UNICANCER (9)
United States (551) · France (132) · Canada (123) · Germany (121) · Spain (117) · Italy (110) · United Kingdom (99) · Belgium (95) · Poland (80) · Netherlands (62) · South Korea (62) · Hungary (60) · China (58) · Australia (52) · Czechia (48)
Leonard B. Saltz, MD (6) · Michael Camilleri, MD (5) · Howard S. Hochster, MD (4)
PMID 28712102, PMID 30721964, PMID 38592721, PMID 22070868, PMID 23493136, PMID 26049686, PMID 26893500, PMID 28103904, PMID 31803504, PMID 32698790, PMID 32816630, PMID 33416261, PMID 34213592, PMID 34289971, PMID 35100697, PMID 37119510, PMID 37934000, PMID 39778975, PMID 10493478, PMID 11762804, PMID 11919232, PMID 12448660, PMID 12621133, PMID 12860947, PMID 14673042, PMID 14745444, PMID 15160338, PMID 15169795, PMID 15289858, PMID 15641483, PMID 15668285, PMID 15709193, PMID 15712779, PMID 15895230, PMID 15908664, PMID 16009952, PMID 16061869, PMID 16062074, PMID 16110021, PMID 16230673, PMID 16361624, PMID 16446336, PMID 16452199, PMID 16502354, PMID 16600979, PMID 16618953, PMID 16622264, PMID 16683076, PMID 16790085, PMID 16849749
2017 (22), 2016 (20), 2009 (18), 2008 (14), 2018 (12), 2014 (8), P30CA015083 (8), 2015 (6), 2019 (6), 2023 (5), P30CA016672 (4), U10CA032102 (4), P30CA016087 (3), U10CA031946 (3), UL1RR024150 (3)